CTLA4 and cancer: Consequently, PD-1/PD-L1 inhibitors have become the backbone of immunotherapy across multiple cancer types, whereas CTLA-4 inhibitors are now most commonly used in combination regimens, where the benefit of synergistic immune activation outweighs the toxicity limitations, as exemplified by the NIVO + IPI regimen for unresectable PM.